beta

BIAF

BioAffinity Technologies Inc

Chart

Stats

Earnings

News

Splits

Dividends

Earnings

Actual EPS
Consensus EPS
Estimated EPS
Number of Estimates
EPS Surprise

Stats

Summary

addressing a critical need to find cancer early and treat cancer specifically bioaffinity technologies, inc. develops tests and therapies to detect and treat cancer at the cellular level. our first product, cypath® flow cytometry for lung cancer (cypath® lung), has been licensed by precision pathology services for continued development and commercial sale as a laboratory developed test. cypath® lung has the potential to dramatically increase overall diagnostic accuracy leading to increased survival, fewer unnecessary invasive procedures and lower patient anxiety and medical costs.

Market Cap: 14.3 Million

Primary Exchange: NASDAQ

Website:

Shares Outstanding: 9.5 Million

Float: 0

Dividend: 0.0 (0.0%)

Beta: 0.35290433947051564

Sector: Professional, Scientific, and Technical Services

Industry: Research and Development in Biotechnology

Ethical Flags

Longest drawdown: 454 trading days

From: 2022-09-02 To: 2024-03-07

Lowest Point:

Ex-Date Payment Date Record Date Declared Date Amount Flag Dividend Type Qualified Indicated
Ex-Date Declared Date Record Date Payment Date Ratio To Factor For Factor
Data provided by IEX Cloud